The DAX continues to consolidate between €23,000 and €24,500, with the 50-day EMA acting as a key pivot and pullbacks still offering potential buying opportunities.
Full FDA approval for one of its drugs, an excellent earnings report, and a deep pipeline support the bullish trend. Is there more room to the upside for Amgen?